Participated · Equity · Oct 2022

Founded in 2020 and led by CEO Nathan Ough, VoltaGrid is a Houston-based advanced energy management and generation company providing behind-the-meter generation, portable power, CNG fuel supply, infrastructure, and energy management services. Its customers include data centers, AI infrastructure, utilities, and industrial clients across North America and beyond. The company reports an order book of roughly 7.5 GW through 2030. VoltaGrid plans to expand deployment and strengthen supply-chain and manufacturing capabilities following its announced acquisition of Propell Energy Technology Ltd., which adds about 1,000 employees and experience in reciprocating engines and turbine technologies. The recent $1.0 billion strategic equity investment is intended to accelerate those deployments and reduce execution risk on its projects.

Led · Series B · Apr 2021

Clir offers a cloud-based AI platform that ingests operational data, cleans and analyzes it with proprietary algorithms, and provides actionable insights to maximize annual energy production and clarify asset performance. Since founding in early 2017, the company has supported over 10 GW of assets worldwide and serves customers that collectively own more than 10% of global installed wind and solar capacity. Clients typically see increases of up to 5% in Annual Energy Production in the first year. The business sells tools to asset owners and managers for optimization across the asset lifecycle, including operations, financing, insurance and repowering. The CAD$27 million Series B will fund further development of ‘smart’ products using industry-wide data to better evaluate technical and financial risk. Clir plans to accelerate growth in its existing European and North American markets and expand into Latin America, Africa and Asia‑Pacific.

Participated · Series C · Oct 2020

MessageBird offers an omnichannel communications platform and developer-facing API that lets companies add messaging, voice, email and chat channels to apps and websites. Its product set includes Inbox for customer service, Campaign Builder for marcomms, Video, and a full API suite for developers. The company supports channels such as SMS, WhatsApp, Instagram, Google Business Messages, Apple Business Chat, Voice and email, and sells both pre-built “lego block” solutions and customizable integrations. MessageBird says the acquisition of SparkPost will bring the industry’s largest email sending and deliverability platform into its suite and help expand its US presence. Financially, MessageBird raised an extended $1 billion Series C that values the company at about $3.8 billion and marks the largest Series C in Europe to date. Founded in 2011 by Adriaan Mol and Robert Vis, the company has pursued M&A previously (including the £26M purchase of Pusher last year) as it moves toward an IPO. MessageBird, founded in 2011 and based in Amsterdam, offers an omnichannel platform‑as‑a‑service that lets businesses communicate with customers across WhatsApp, Messenger, WeChat, Twitter, SMS, email, voice and more via APIs and an omni‑channel chat widget. The company repositioned from a Twilio competitor to an OPaaS focused on enabling enterprises and SMBs to move customer interactions seamlessly across channels. MessageBird says one‑third of its 15,000 customers have adopted its omnichannel products and the company is on track to do €300 million in annual revenue. It spent its first six years largely bootstrapped and claims to have been profitable from day one. The funding will be used to triple the size of its global team, expand in Europe, Asia and Latin America, and pursue potential M&A and product investments. MessageBird is also investing in automation within its Flow Builder product with ambitions for RPA‑style capabilities for external business messaging. MessageBird is an Amsterdam-founded cloud communications platform that offers voice, video and text capabilities via APIs. The company operates its own telecoms infrastructure and has direct integrations with 220 carriers globally, which it says reduces hops, cost and latency compared with competitors. Historically it has targeted larger enterprise customers and built direct carrier relationships to compete on price, reliability and security. MessageBird counts 15,000 international customers, including DoorDash, SAP, Huawei, ING, Amber Alert, Heineken and Uber. The company has been profitable since day one, was largely bootstrapped and Y Combinator-backed, and is on track to hit a $100 million run rate this year. To meet rising inbound demand and scale its teams, the company raised external funding despite profitability to accelerate growth.

Led · Equity · Feb 2013

Domainex is a privately owned drug discovery company founded in 2002 and based in Cambridge, UK. It develops small-molecule programs supported by a discovery platform built around Combinatorial Domain Hunting (CDH), LeadBuilder virtual screening, and integrated medicinal and computational chemistry. The company also operates a service business that recently won new translational-research contracts with UK universities. Its internal development programs focus on kinase targets TBK1/IKKe and an epigenetics portfolio targeting lysine methyltransferases. Management says it is approaching selection of a clinical candidate for the TBK1/IKKe programme and will use part of the new investment to move that programme toward an out-licensing deal; the majority of funds will progress the epigenetics portfolio. Three compounds from Domainex collaborations are in clinical evaluation and two additional drugs are in preclinical studies. Domainex is a biopharmaceutical company. It was spun out from University College London, The Institute of Cancer Research and Birkbeck College London. Longbow Capital led an investment in the company. The Capital Fund also participated alongside Longbow Capital. The two investors together invested

Participated · Equity · Nov 2010

RepRegen is a London-based medical device company that develops products to repair and restore tissue using repair and regeneration technology across two platforms. One platform targets bone and other hard tissues; the other focuses on muscle and other soft tissues. The company is commercializing its first hard-tissue product, StronBone™, a strontium-containing bioactive glass bone graft substitute with CE Marking for orthopaedic (trauma and spine) and craniomaxillofacial applications. StronBone has not been cleared by the FDA and is limited to investigational use in the U.S. RepRegen raised new capital to continue advancing its product pipeline, pursue regulatory approvals, support commercialization programs and prepare for relevant post-market clinical studies. The company intends to deploy the funds to move products through regulatory and commercial milestones.